Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022 | Company
MARSEILLE, France–(BUSINESS WIRE)–Sept. 5, 2022–
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate “or the” Company ”) announced today that the following presentations will be presented at the 2022 Annual Meeting of ESMO (European Society for Medical Oncology) to be held September 9-13, 2022, in Paris, France.
- A Multicenter Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapsed or Refractory KIR3DL2-Expressing Peripheral T-Cell Lymphoma
– Abstract number: 647TiP
– Session type: Trial in progress poster
– Session title: Malignant hematology
– Date of the session: Sunday, September 11, 2022
– Presenter: Marianna Muller, MD, PharmD, Director of Clinical Development at Innate Pharma
- Oral Presentation: Multispecific Antibody Design: ANKET for Antigen-Specific Activation of NK Cells
– Type of session: Special session
– Session Title: Next Frontiers in Drug Discovery
– Date and time: Monday, September 12, 2022 from 9:05 a.m. to 9:20 a.m. CEST
– Location: 7.3.U – Urval Auditorium
– Speaker: Eric Vivier, DVM, PhD, Scientific Director of Innate Pharma
- Oral presentation: Study of neoadjuvant durvalumab (D) platform alone or in combination with new agents in patients (pts) with resectable early-stage non-small cell lung cancer (NSCLC): pharmacodynamic correlates and dynamics of circulating tumor DNA (ctDNA) in the NeoCOAST study [AstraZeneca-sponsored]
– Presentation #929MO
– Type of session: Mini oral session
– Session title: Non-metastatic NSCLC and other thoracic malignancies
– Date and time: Monday, September 12, 2022 at 3:15 p.m. CEST
– Location: 7.3.O – Orléans Auditorium
– Presenter: Jonathan Spicer (Montreal, Canada)
The poster and the presentations will be available on the Publications section of innate-pharma.com after the presentation.
Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 cytotoxicity-inducing humanized antibody currently in clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and T-cell lymphoma T device (PTCL). Rare cutaneous T-cell lymphomas have a poor prognosis with few effective and safe treatment options in advanced stages.
KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients in all CTCL subtypes and expressed by up to 90% of patients with certain aggressive CTCL subtypes, in particular Sézary. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues.
ANKET™ ( A antibody-based NK cell E engage J herapeutics) is Innate’s proprietary platform for the development of next-generation multispecific natural killer (NK) cell engagers to treat certain types of cancer.
This versatile and adaptive technology creates an entirely new class of molecules to induce synthetic immunity against cancer. It harnesses the benefits of harnessing NK cell effector functions against cancer cells and also provides targeted proliferation and activation signals to NK cells.
Our latest innovation, the tetra-specific ANKET molecule, is the first NK cell engagement technology to engage activating receptors (NKp46 and CD16), tumor antigen and interleukin-2 receptor (via a variant of the IL-2, IL-2v) via a single molecule.
Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating CD8+ cytotoxic T cells and NK cells.
NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves against destruction by NKG2A+ immune cells. HLA-E is frequently overexpressed in cancer cells of many solid tumors and hematological malignancies. Monalizumab may restore a broad NK and T cell-mediated anti-tumor response, and may increase the cytotoxic potential of other therapeutic antibodies 1.
Ongoing development of monalizumab focuses on studying monalizumab in various combination strategies in different malignancies, including, in early-onset lung cancer, the Phase 3 PACIFIC-9 study in adults with locally advanced (stage III), unresectable NSCLC who did not progress after concurrent platinum-based chemoradiotherapy and the NeoCOAST-2 phase 2 study in the early neoadjuvant setting of NSCLC.
About Innate Pharma:
Innate Pharma SA is a clinical-stage oncology-focused global biotechnology company dedicated to improving treatments and clinical outcomes for patients through antibody therapeutics that harness the immune system to fight cancer.
Innate Pharma’s large antibody portfolio includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in understanding Natural Killer cell biology and has expanded its expertise in tumor microenvironment and tumor antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry, including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-product collaboration with AstraZeneca.
Based in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the United States.
Learn more about Innate Pharma at www.innate-pharma.com
Information on Innate Pharma shares:
Euronext: IPH Nasdaq: IPHA
Disclaimer of forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe”, “potential”, “expect” and ” will” and similar expressions, is intended to identify forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among others, uncertainties inherent in research and development, including those relating to the safety, progress and results of its ongoing and planned clinical trials and preclinical studies, the review and the approval by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to finance its development. For a further discussion of the risks and uncertainties that could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors section. (“Risk Factors”) of the Universal Registration Document filed with the Autorité des Marchés Financiers (“AMF”), available on the AMF’s website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31 2021, and subsequent filings and reports filed with the AMF or the SEC, or otherwise made public, by the Company.
This press release and the information it contains do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares of Innate Pharma in any country whatsoever.
1 André et al, Cell 2018
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220904005030/en/
CONTACT: For more information:Investors and MediaInnate Pharma
Such. : +33 (0)4 84 90 32 88
Delphine Lens (France)
Such. : +33 (0)9 81 87 46 72
KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE
SECTOR KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICALS CLINICAL TRIALS ONCOLOGY
SOURCE: Innate Pharma SA
Copyright BusinessWire 2022.
PUBLISHED: 05/09/2022 01:00/DISC: 05/09/2022 01:02